Clinical trial · Interventional
Pilot Study: Use of the Saccadometer to Detect Characteristic Saccadic Peak Velocity in Myasthenia Gravis Patients
NCT06501794CI-TRIAL-00083878completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Fast eye movements have been shown to demonstrate characteristics that are specific to myasthenia gravis that are not present in other eye movement disorders. It is possible to measure these eye movements and potentially identify these characteristics using new portable eye movement testing equipment. The aim of this pilot study is to discover if these characteristics can be identified using portable eye movement testing equipment in patients with a confirmed diagnosis of myasthenia gravis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myasthenia Gravis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quantitative measurement of eye movements | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Myasthenia Gravis
- description
- Participants with a confirmed diagnosis of Myasthenia Gravis
- interventionNames
- Device: Quantitative measurement of eye movements
Primary outcomes (1)
- measure
- Saccadic Peak Velocity
- timeFrame
- Measured at first and only contact point within study i.e. day one and then not tested again
- description
- Participants will be recruited, consented and tested at a single visit during their routine clinical visit, up to one year after being recruited. Quantitative assessment of their eye movements using the Saccadometer will be assessed at that point of contact and the outcome measure recorded.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patient participants * Confirmed diagnosis of Myasthenia Gravis by either a positive acetylcholine antibody serum test (AChR) and/or a positive single fibre electromyograph (SFEMG) test. * Patient participants must have also had at least one episode of diplopia and/or eye movement abnormality attributed to their diagnosis of MG. Healthy participants: * Must have no history of eye movement abnormality * No have no history of other auto-immune disease (specifically diabetes, Thyroid Eye Disease and Chronic External Ophthalmoplegia). Exclusion Criteria: * Patients without confirmed Myasthenia Gravis diagnosis by means of either a positive AChR serum test and/or a positive SFEMG test. * Patients with confirmed Myasthenia Gravis who have not had at least one episode of diplopia and or ptosis. * Patients with current or previous episodes of ocular motility dysfunction that have a confirmed diagnosis other than Myasthenia Gravis. * Any healthy participant found to have an abnormality of vision or eye movement upon screening or a history of auto-immune disease.
References
Publications (0)
Data not yet available
No reference posted for this study.